|WHEN||October 05, 2013 @ 8:00am - 5:00pm|
When: 8:15 am – 5:00 pm, Saturday, October 5, 2013
Photo Report: http://xiangce.baidu.com/u/1564308656
$20 for early birds by Sept 30, $30 for online regular registration by Oct. 03; $50 for onsite registration (cash or check onsite); $10 off for students and postdocs. Fees include program brochure, continental breakfast, coffee breaks, lunch and onsite reception.
The 9th SABPA Pacific Forum will be held on Saturday Oct. 5, 2013 at the Institute of the Americas, UCSD. As one of the flagship annual conferences organized by SABPA, Pacific Forum (PF) draws about 300 life sciences professionals from across the Pacific every year. The main themes of this year’s conference will include 1) cross-border collaborations in the pharmaceutical and biotech field that have effectively integrated resources to fuel innovative R&D and business in the Pacific Rim, and 2) recent trends in applying genomic technologies to improving human healthcare. Senior leaders from the R&D divisions of pharmaceutical and biotech companies, international IP experts, world-renowned researchers from universities and academic institutions, and executives of organizations from the Asia Pacific region will share their insights on a variety of exciting topics at this event.
Event Program (Download printable PDF Brochure here)
8:15 am Breakfast and Registration
8:45 am Welcoming
Mingzhu Zhang, Ph.D. – President, SABPA, San Diego Chapter; VP of Business Development, Shanghai Medicilon
Yung-Chih Wang, Ph.D., MBA – Chair, Pacific Alliance, SABPA; VP, Corporate Dev., China, HUYA Bioscience
9:00 am San Diego’s Conducive Environment for Trans-Pacific Collaboration
Ron Roberts, M.Arch. – Supervisor, Fourth District, San Diego County Board of Supervisors
9:10 am China-US Collaborations in a Boundaryless World
William Brody, M.D., Ph.D. – President, Salk Institute [Download Slides]
9:40 am Cancer Research: Leveraging Global Partnerships to Address the Burden of a Global Disease
Steven Adams, Ph.D., DVM – Chief Operating Officer, Oncology Research Unit, Pfizer [Download Slides]
10:10 am The Ever Changing Phase of CROs in China
Chen Chen, Ph.D. – Chief Executive Officer, Sundia MediTech [Download Slides]
10:20 am Coffee Break
10:50 am From an Emerging Market to an Emerging Innovator
Will Liu, Ph.D. – Head of External Innovation, R&D Beijing Hub, Merck Serono
11:20 am Discovery and Development of Biopharmaceutics in China
Zeling Cai, Ph.D. – Senior Vice President, Shanghai Celgen Biopharm
11:50 am Leveraging the Power of Real Time Cell Analysis for Risk Assessment of Pharmaceutical Compounds, Detection of Bacterial Toxins and for Vaccine Development: Joint Collaboration Between ACEA Biosciences, Zhejiang CDC, China National Drug Safety Center and Fudan University
Yama Abassi, Ph.D. – Vice President, ACEA Life Technologies [Download Slides]
12:10 pm Lunch
1:45 pm Opening of Afternoon Sessions
Stephanie Shi, Ph.D.- Co-Chair, Pacific Alliance, SABPA; Integrated Sourcing Lead, External Res. Solutions, Pfizer
1:50 pm Implications of Myriad on IP Protection for Personalized Medicine and Protecting IP in US and China
Peng Chen, Ph.D., J.D. – Partner, Morrison & Foerster [Download Slides]
2:20 pm Genomic Applications at the Frontiers of Cancer Management
Daniel S. Grosu, M.D. – Vice President, Clinical Development & Medical Affairs, Illumina
2:50 pm Global Delivery of Precision Medicine.
Paul Billings, M.D., Ph.D. – Chief Medical Officer, Life Technologies [Download Slides]
3:20 pm Coffee Break
3:50 pm Panel Discussion: Genomics Service-Delivering the Promise of Sequencing Now [Download Slides]
Xing Yang, Ph.D. – Vice President, System Development, BioNano Genomics
Ardy Arianpour, MBA – Senior VP of Business Development, Ambry Genetics
Amy Liao, Ph.D. – President & Chief Operating Officer, GeneWiz
Michael Nova, M.D., Ph.D. – Chief Medical Officer, Pathway Genomics
Joyce Peng, Ph.D. – Marketing Director, BGI
4:50 pm Closing Remarks
5:00 pm Close of Forum
Pre-Forum Event: Introduction of UNISource 江苏产业技术国际研究院;
Friday, October 4, 6-8 pm, at MoFo (12531 High Bluff Drive, Suite 100, San Diego, CA 92130);
free registration at a separate site https://sabpa.org/web/reg_2013_unisource.php , including complimentary light dinner.
Presentation: Collaboration to Develop Business and Share Resources between Jinagsu China and California USA
Speaker: Adam Zhu, Dean of Research Institute of Jiangsu Industrial Technology
(Presentation and discussion will be conducted in Chinese)
Research Institute of Jiangsu Industrial Technology (UNISource Co.) is a wholly-owned subsidiary of Jiangsu Zhongsheng Zhiyuan Technology Industry Co., Ltd. while US Research Institute of Jiangsu Industrial Technology (based in Silicon Valley) is a branch of Research Institute of Jiangsu Industrial Technology.
UNISource Inc. and US Research Institute of Jiangsu Technology are co-founded by 10 Jiangsu IT companies. The US Institute is a business unit providing technology R&D and innovation services for enterprises. It focuses on the IT industry and the emerging strategic industries including new materials, new energies and bio-medicine.
The Institute is organized to integrate global innovation resources, serve US and China enterprises, promote industrial innovation, and enhance enterprises’ R&D capabilities. It strives to become one of the best and world-influential technology innovation companies in China, an innovation source of Sino-US industrial technology R&D, and an accelerator of cultivating emerging industries in five years.
Current Corporate Sponsors
For sponsorship information, please contact Li-Ming Liang ( firstname.lastname@example.org )
Speaker Bio (in alphabetical order of last names)
Yama Abassi, Ph.D.
Senior Scientific Director and VP, ACEA Biosciences
Dr. Yama A. Abassi is Senior Scientific Director and VP at ACEA Biosciences. Dr. Abassi received his undergraduate degree in biochemistry with Honors from State University of New York/Stony Brook in May of 1992 and a PhD degree in Molecular, Cell and Developmental Biology from University of California at Santa Barbara in 1999. Dr. Abassi joined the Burnham Institute for Cancer Research as an NIH Post-Doctoral fellow in 1999 and performed his postdoctoral work in delineating oncogene signaling pathways and its role in cancer biology. Dr. Abassi joined ACEA Biosciences in 2003 and has numerous publications, SBIR awards and patents in the application of impedance technology for cancer research, GPCR signaling, immune function, drug discovery and toxicity.
Steven Adams, Ph.D., DVM
Chief Operating Officer, Oncology Research Unit, Pfizer
Steven Adams is Senior Director of Operations for the Pfizer Oncology Research Unit (ORU) and has more than 20 years experience in a diverse range of business and scientific roles within the biopharmaceutical industry. Steve and his team are currently accountable for ORU operational infrastructure, resource and portfolio strategy, and operational and business support for external sourcing, alliances and collaborations. Dr. Adams joined Pfizer in 2000 where he led the scientific and operations staff of Comparative Medicine and in 2006 moved to R&D Business Development where he was Business Development Lead for the Oncology Research Unit and established numerous scientific collaborations across Asia. During 2010 Dr. Adams also served as Head of Asia R&D Business Development before assuming his current role in the ORU in early 2011. Prior to joining Pfizer, Dr. Adams has held leadership positions in preclinical development, laboratory animal medicine, and outsourcing. He also founded and led a successful CRO providing pharmacology, toxicology and pathology services to the Biopharma community. Dr. Adams received his Doctor of Veterinary Medicine from the University of California, Davis and his PhD in viral immunology from the University of Florida. He is board certified by the American College of Laboratory Animal Medicine.
Ardy Arianpour, MBA
Senior VP of Business Development, Ambry Genetics
Mr. Arianpour joined Ambry Genetics in April of 2009 and currently serves as Senior Vice President of Business Development, responsible for all corporate business development activities, including strategic planning, corporate partnerships and alliances. Mr. Arianpour developed the Genomics division in early 2009 at Ambry Genetics and oversees worldwide sales. Before joining Ambry Genetics, Mr. Arianpour was Manager of Business Development at Cogenics, a division of Clinical Data. Prior to that, he was with Eurogentec North America and DMI Medical in senior sales roles managing and building business opportunities both domestically and internationally. Mr. Arianpour has 12+ years of experience in life science sales, business development and strategic planning. He holds a B.S. in Biological Sciences from the University of California, Irvine and an MBA in Strategic Management from Marshall Goldsmith School of Management at Alliant International University / University of California, San Diego.
Paul Billings, M.D., Ph.D.
Chief Medical Officer, Life Technologies
Dr. Paul R. Billings serves as Chief Medical Officer of Life Technologies Corporation (NASDAQ: LIFE), a unique position aimed at improving patient care through expanding the use of medically relevant genomic technologies in clinical settings. He currently serves on the Scientific Advisory Board of the Food and Drug Administration, the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics.
Dr. Billings has had a distinguished career as a physician and researcher. He has been a founder or CEO of companies involved in genetic and diagnostic medicine including GeneSage Inc., Omicia Inc. and CELLective Dx Corporation and was SVP for corporate development at Laboratory Corporation of America Holdings (NYSE; LH). He has held academic appointments at some of the most prestigious universities in the US and has served as a physician at a number of prestigious medical centers. He is the author of nearly 200 publications and books on experimental and clinical medicine.
Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology from Harvard University. Prior to their recent transactions, Dr. Billings was a Director of Ancestry.com (NASDAQ: ACOM), the Executive Chairman of Signature Genomics Inc., and a Founder of the Cordblood Registry, Inc. He is a long time Board Member of the Council for Responsible Genetics, the country’s oldest independent biotechnology “watchdog” organization.
William Brody, M.D., Ph.D.
President, Salk Institute
Dr. Brody is an acclaimed physician scientist. A native of Stockton, California, Dr. Brody received his B.S. and M.S. degrees in electrical engineering from the Massachusetts Institute of Technology, and his Ph.D. and M.D. (cardiac surgery), from Stanford University. Prior to Salk, he was president of The Johns Hopkins University for 13 years, and before that, he was the provost of the Academic Health Center at the University of Minnesota. Prior to Minnesota, he was the Director of the Department of Radiology, professor of electrical and computer engineering, and professor of biomedical engineering at Johns Hopkins University, and radiologist-in-chief of The Johns Hopkins Hospital.
Dr. Brody serves on the board of directors of IBM and Novartis AG, and serves as a Trustee of Stanford University. He is a member of the Institute of Medicine and the National Academy of Engineering, and is a fellow of the Institute of Electrical and Electronic Engineers, the American College of Radiology, the American College of Cardiology, the American Heart Association, the International Society of Magnetic Resonancein Medicine, the American Institute of Biomedical Engineering, and the American Academy of Arts and Sciences.
Zeling Cai, Ph.D.
Chief Scientific Officer, Celgen
Dr. Zeling Cai is a Senior Vice President at Shanghai Celgen Biopharm (上海赛金生物医药有限公司) with responsibility for discovery and development of biopharmaceutics. Shanghai Celgen Biopharm has successfully brought Qiangke (强克™）, an anti-inflammation biologic, to the Chinese market. Prior to joining Shanghai Celgen Biopharm, Dr. Cai was a research fellow and a director in drug discovery and early development at the Johnson & Johnson Pharmaceutical Research & Development. Dr. Cai obtained her PhD in Immunology from the Mayo Graduate School and received her post-doctoral training at The Scripps Research Institute. She has published over 30 papers in number of journals and has filed more than 30 patents and many of them have been issued. She has been a member of American Association of Immunologists since 1998 and a member of International Society of Biological Therapy of Cancer since 2004.
Chen Chen, Ph.D.
Chief Executive Officer, Sundia MediTech
Dr. Chen has a Ph.D. in Organic Chemistry from the Shanghai Institute of Organic Chemistry, China. He did a post-doc at Texas A&M University with Nobel Laureate, Professor Sir Derek H. R. Barton, and a post-doc at the University of Illinois, Chicago. Dr. Chen spent 15 years at Neurocrine as Scientist to Senior Director of Medicinal Chemistry. In his research and management positions at Neurocrine, Dr. Chen achieved many outstanding scientific and industrial accomplishments, including development of two small molecule antagonists, NBI-42902 and elagolix (aka NBI-56418), of the gonadotropin-releasing hormone receptor into clinical studies, and the later one is currently in Phase III clinical trials. Dr. Chen Chen has served as Sundia’s Senior Vice President since 2009. And he has been appointed as CEO of Sundia in 2012. Dr. Chen has extensive experience in CNS drug research and GPCRs as drug targets. His knowledge also includes neuropathic pain and metabolic disorders. His research interests extend to clinic and preclinical pharmacokinetics of small molecules and the relationship with their chemical properties.
Dr. Chen has so far published near 130 scientific papers in peer-reviewed journals such as J. Am. Chem. Soc., J. Org. Chem., J. Med. Chem., and J. Biol. Chem. He has written numerous review articles on the topics of drug discovery and medicinal chemistry. He is the co-inventor of over 25 US patents. He has been invited to give presentations in numerous scientific conferences such as the Gorden Research Conference of Medicinal Chemistry and the ACS National Meeting.
Peng Chen, Ph.D., J.D.
Partner, Morrison & Foerster
Peng Chen leads his biotechnology, pharmaceutical, and diagnostics clients through the technical and legal challenges involved in developing and protecting their critical IP assets. Dr. Chen’s practice focuses on patent prosecution and counseling and he also is experienced in the areas of patent litigation, reexamination, interference, opposition, and licensing.
For numerous clients, Dr. Chen manages entire patent portfolios, advising the clients on maximizing their patent positions and designing patent strategies. On behalf of one client, he obtained U.S. patent protection for its novel diagnostic test and advised the client in designing around a third party’s patents. When the third party threatened to sue the client, he worked with several Morrison & Foerster patent litigators in obtaining summary judgments of non-infringement twice from the District Court, and eventually won the appeal from the Federal Circuit. (General Atomics Diazyme Labs. Div. v. Axis-Shield ASA, 277 Fed. Appx. 1001, 2008 U.S. App. LEXIS 10235 (Fed. Cir. 2008)).
While earning his B.S., Dr. Chen was on the Dean’s List. After receiving his Ph.D., Dr. Chen conducted his post-doctoral fellowship at Yale University School of Medicine. He was also a Harlan Fiske Stone Scholar while in law school.
Daniel S. Grosu, M.D., M.B.A
Vice President, Clinical Development & Medical Affairs, Illumina
Dr. Daniel Grosu is the Vice President of Clinical Development and Medical Affairs at Illumina. He has a longstanding interest in innovative cancer diagnostics spanning previous assignments with Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Johnson & Johnson. Dr. Grosu holds an MD (with Distinction in Research) from Saint Louis University School of Medicine and an MBA from the University of Oxford.
Amy Liao, Ph.D.
President & Chief Operating Officer, GeneWiz
Dr. Amy Liao is the President and Chief Operating Officer of GENEWIZ Inc. Amy is a co-founder of GENEWIZ and has held a critical leadership role in the company’s growth since its founding in 1999.
Amy received B.S. in Biochemistry from Nankai University, China, and M.S. in Biochemistry from Tsinghua University, China, before she obtained her Ph.D. in Biochemistry and Cell Biology from SUNY at Stony Brook. Amy did her postdoctoral training in Biochemistry and Cell Biology at Columbia University before she left to found GENEWIZ.
Together with her GENEWIZ team members, Amy worked to expand GENEWIZ both nationally and globally. GENEWIZ is a contract research organization (CRO) specializing in DNA-based services including DNA sequencing, gene synthesis, molecular biology, genomic services, and GLP/cGMP/CLIA regulatory services. Headquartered in NJ, GENEWIZ is a global enterprise with additional laboratory locations in Boston, San Diego, Washington D.C. Metro, Research Triangle Park, Seattle, San Francisco, Suzhou, China, and Beijing, China.
Along with the GENEWIZ co-founder, Dr. Steve Sun, Amy was selected as the New Jersey winner for the Ernst & Young Entrepreneur Of The Year® 2010, the world’s most prestigious business award for entrepreneurs. NJBIZ named GENEWIZ 2011 Business of the Year, an award that recognizes businesses and business leaders that made significant contributions to the growth of New Jersey.
Will Liu, Ph.D.
Head of External Innovation, R&D Beijing Hub, Merck Serono
Dr. Will Liu is the Head of External Innovation China at Merck Serono, where he is responsible for the development of innovative opportunities in life science and biotechnology in the Greater China region. Prior to joining Merck Serono, he was the Director of Innovation Management at Bayer Healthcare Global R&D Center China. During his tenure at Bayer, he was responsible for external collaborations with academia and industry, as well as in- and out-licensing of early phase assets in the region. Dr. Liu has extensive experience in the pharmaceutical and biotech industries, ranging from drug discovery to business development. He received his Ph.D. degree in organic chemistry from the University of Michigan.
Michael Nova, M.D., Ph.D.
Chief Medical Officer, Pathway Genomics
Dr. Nova is currently the chief medical officer of Pathway Genomics. His scientific career began as a research associate at the Salk Institute in the laboratory of Nobel Laureate Roger Guillemin, where he studied the genetics and proteomics of Human Growth Factors. Michael was the founder and CEO of Discovery Partners Inc. (Nasdaq: DPII), which completed a successful $150M IPO and marketed wireless drug discovery technology and radiofrequency combinatorial chemistry to large pharmaceutical companies. He then founded the wireless sensory network company Graviton, where he was responsible for raising $60 million in capital from venture groups such as Kleiner Perkins and InQtel and additional. Dr. Nova is also a 2005 World Economic Forum Technology Pioneer Award Winner; and the physician of record for the first person ever to have their entire genome sequenced by Illumina (2009).
Dr. Nova has over 20 issued and pending patents. He has numerous publications in peer-reviewed journals, and is a Board-certified Dermatologist and Dermatopathologist licensed in California. In his minimal spare time, Michael likes to surf big waves in Indonesia, and he also helped start a WHO-sanctioned basic care clinic in the Fijian town of Nabila.
Joyce Peng, Ph.D.
Marketing Director, BGI
Dr. Joyce Peng has established herself as a prominent voice for the application of state-of-the art technologies in the life sciences field. Joyce has been promoting bioinformatics and related products at various organizations and is now marketing director at BGI Americas Corporation. She helped define the product line for Oracle in life sciences as a senior product manager. Subsequently, Joyce established proteomics product directions for Rosetta Biosoftware (a subsidiary of Merck) and managed bioinformatics product sales for North America at Life Technologies. In her position as the strategic alliance and growth manager at Illumina, Joyce managed the partnership with BGI and advanced the application of various sequencing technologies. Now, in her role as marketing director at BGI Americas, Joyce is active in promoting collaborations and alliances with pharmaceutical and biotechnology organizations for the application of BGI’s world-renowned sequencing services. Joyce holds a Ph.D. in Biology from Caltech.
Ron Roberts, M.Arch.
Supervisor, Fourth District, San Diego County Board of Supervisors
Supervisor Ron Roberts represents 626,000 residents of San Diego County’s Fourth Supervisorial District. After graduating with a master’s degree in architecture from the University of California, Berkeley, Roberts spent 20 years as a practicing architect. In 1987 he won a seat on the San Diego City Council and then seven years later on the San Diego County Board of Supervisors.
Roberts founded The Asia Desk at the San Diego World Trade Center. He has traveled throughout Asia, meeting with top officials to discuss mutually beneficial partnerships. In San Diego, he regularly hosts international students and delegations at his office along the downtown waterfront.
As a member of the California Air Resources Board, Roberts has helped craft air-emission regulations that, along with local initiatives, have given urban San Diego its cleanest air in decades. During his travels, Roberts has spoken to Asian leaders and university students about how California cleaned up its air, encouraging them to develop an approach that meets their clean air goals and objectives.
Supervisor Ron Roberts and his wife live in the same home they built and where they raised their three daughters, all of whom are now successful professionals. The couple has three grandchildren.
Xing Yang, Ph.D.
Vice President, System Development, BioNano Genomics
Dr. Xing Yang currently serves as Vice President, System Development at BioNano Genomics, a whole genome analysis company. In his more than a decade of experience in the biotechnology industry, Dr. Yang was involved in several successful startup companies. Prior to joining BioNano Genomics in March 2011, he was Vice President of Technology and a co-founder of Epic Sciences, a cancer diagnostics company focusing on capture and characterization of circulating tumor cells. Previously, Dr. Yang was Vice President of Research at Helixis, a real-time PCR instrumentation company acquired by Illumina. Before that, he was Senior Director of Development at BD Diagnostics-GeneOhm. Dr. Yang received his Ph.D. in Electrical Engineering from the California Institute of Technology.
Adam Zhu, MBA
Executive Dean, Research Institute of Jiangsu Industrial Technology
Mr. Adam Zhu graduated from Guangzhuo School of Management, Peking University with an MBA degree. He is currently the Dean of Research Institute of Jiangsu Industrial Technology (UNISource Co.).
Mr. Zhu and his partner co-funded Nanjing Jkom, Inc., which is committed to the development of health care and technology industries. It creatively integrated traditional medicine and modern communications technology. The development of doctor-patient communication platform, intelligent nutrition catering system, intelligent self-diagnosis system, 3D network virtual hospital, and diabetes hospital management system are domestic initiative.
Mr. Zhu has served as the News Director of Jiangsu Province Network News, China’s Chief Operating Officer of U.S. listed company, well-known Silicon Valley software company PalmSource. Inc.(1999-2003), and COO in Japan ACCESS technology Chinese companies (2003-2005). Mr. Zhu has a wealth of experience in the operational management of international large enterprises.